Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cGAS inhibitor (Leuven Centre for Drug Design and Discovery)
- Development stage
- Preclinical
- Lead developer
- Leuven Centre for Drug Design and Discovery
- Modality
- Small Molecules
01
Overview
This program involves the development of small molecule inhibitors targeting cyclic GMP-AMP synthase (cGAS), an enzyme that acts as a cytosolic DNA sensor. Upon binding to double-stranded DNA, cGAS produces the second messenger cyclic GMP-AMP (cGAMP), which activates the Stimulator of Interferon Genes (STING) pathway, leading to the production of Type I interferons and other pro-inflammatory cytokines. Dysregulation of this pathway is implicated in various autoimmune and inflammatory diseases, such as Aicardi-Goutières syndrome (AGS), systemic lupus erythematosus (SLE), and other interferonopathies. The Leuven Centre for Drug Design and Discovery (CD3) is developing these inhibitors to modulate the cGAS-STING axis for the treatment of inflammatory conditions. The project is currently in the preclinical stage.
- Other names
- cGAS inhibitors (CD3)cGAS inhibitors (Leuven Centre for Drug Design and Discovery)
02
Targets
Cyclic GMP–AMP synthase
Beyond the preview
Go deeper on cGAS inhibitor (Leuven Centre for Drug Design and Discovery).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cGAS inhibitor (Leuven Centre for Drug Design and Discovery).